Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old at the time of giving consent to participate.
- People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed through laboratory testing of tissue or cell samples.
- People whose cancer cannot be surgically removed, has spread, and has continued to grow after at least one previous standard cancer treatment — or where standard treatment was not tolerated or was not an option.
- People who have at least one tumour that can be measured using standard imaging criteria.
- People whose tumour tissue tests positive for certain proteins: Arm A requires the tumour to show mesothelin (MSLN) and/or MUC1; Arm B requires the tumour to show Claudin 18.2 (CLDN18.2) and/or MUC1 — tested on stored or freshly taken biopsy samples (confirm with trial site for exact thresholds).
- People with a good general level of physical functioning, rated 0 or 1 on a standard scale used by doctors (meaning fully active or able to carry out light activity).
- People whose blood counts and organ function (including liver and kidneys) meet minimum health thresholds set by the trial (confirm with trial site for exact values).
- People with a life expectancy of at least 12 weeks.
- People who are not pregnant (a negative pregnancy test is required for those who could become pregnant), and those who agree to use effective contraception throughout the study and for a set period afterwards.
- People who are able to understand the study information and are willing to sign a consent form.
Who may not be able to join:
- People who have active or untreated cancer that has spread to the brain or the lining around the brain and spinal cord.
- People with a serious, uncontrolled infection (bacterial, fungal, or viral).
- People with active hepatitis B or hepatitis C where the virus is still detectable in the blood, or people with uncontrolled HIV infection.
- People who have previously had a bone marrow or stem cell transplant from a donor, or a solid organ transplant (such as a kidney or liver).
- People who received a gene-modified cell therapy (such as CAR-T or CAR-NK treatment) within the past 6 months, or who have previously had treatment targeting the same proteins this trial focuses on.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 13076790030
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicities (DLTs); Incidence and severity of treatment-emergent adverse events (TEAEs); Maximum tolerated dose (MTD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.